生物标志物 生物标志物
Molly Olzinski1, Yann Cobigo2, Rowan Saloner1
1Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
概括
下脑脊液 (CSF) TMEM106B水平与前叶退化 (FTLD) 严重程度增加和大脑缩相关. CSF TMEM106B可以作为FTLD中神经退行的一个有价值的生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 生物标志物发现发现
背景情况:
- TMEM106B是一种 lysosomal 蛋白质,是前叶退化症 (FTLD) 的遗传风险因素.
- 基于aptamer的蛋白质组学可以量化CSFTMEM106B.
- 作为FTLD严重程度的生物标志物,CSF TMEM106B的临床实用性尚未评估.
研究的目的:
- 调查CSFTMEM106B水平与FTLD疾病严重程度之间的关联.
- 探索CSF TMEM106B,神经退行和大脑缩之间的关系.
- 确定CSFTMEM106B作为FTLD临床生物标志物的潜力.
主要方法:
- 在两个独立的FTLD队列 (偶发性和家族性) 中,CSF TMEM106B和NfL蛋白质水平使用基于aptamer的蛋白质组测量.
- 统计分析,包括线性和混合线性模型,评估生物标志物和疾病严重程度指标之间的关联 (例如CDR®+NACC-FTLD).
- 基于voxel的形态学分析了CSF生物标志物与大脑体积之间的相关性.
主要成果:
- 较低的CSFTMEM106B水平与更大的FTLD疾病严重程度,功能衰退,认知障碍和抑郁症有关.
- 低的CSFTMEM106B与前额,顶部和部区域的大脑体积减少相关.
- CSF NfL与疾病严重程度的关联较强,而CSF TMEM106B与大脑体积的关联较强.
结论:
- 脑流TMEM106B度受rs1990622基因型的影响,与FTLD疾病严重程度和大脑缩相关.
- 较低的CSFTMEM106B水平表明FTLD中更严重的神经退行和大脑体积损失.
- CSF TMEM106B显示出作为FTLD神经退行症生物标志物的潜力,补充了CSF NfL.
相关概念视频
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516